UNCSTD第22屆副主席致外國專家和國際友人的信

尊敬的外國專家和朋友:

在世界各國友人的關心和支持下，中國人民眾志成城、科學防治，目前疫情防控形勢積極向好，多個省市實現了連續多日新病例零增長。在確保疫情防控到位的前提下，我國政府有序推動企事業單位復工復產，降控經濟發展影響，為世界經濟繁榮與穩定提振信心。

在這場斗爭中，中國廣大科技工作者奮戰在抗擊疫情科研攻關第一線，取得了一些科研成果，在疫情防控中發揮了積極作用。本著公開、透明、真誠態度，我們積極主動同世衛組織和國際社會開展科研合作和信息交流，努力防止疫情在世界蔓延。在此，我謹向大家介紹我所在的廣東省近期為疫情防控和醫療救治提供技術支撐的幾項成功實踐，愿與其他國家分享、對接、合作和提供服務：

一是試用新冠肺炎AI輔助診斷系統。眾所周知，影像學檢查在新冠肺炎的診療中具有非常重要的參考價值。新冠肺炎屬于新發疾病，病程發展快，需要對患者拍攝多次CT以對患者進行確診、監測病情發展、評估治療效果等，單純憑借肉眼閱片醫生很難快速對比并識別病灶變化。廣州再生醫學與健康廣東省實驗室聯合中山大學孫逸仙紀念醫院在50萬份臨床影像學大數據的基礎上，緊急開發了基于胸部CT和X-ray影像學的新冠肺炎AI輔助試行診斷系統，能夠高效、特異區分出新冠肺炎患者和非新冠肺炎患者（包括其他病毒性肺炎、細菌性肺炎和其他發熱患者）。基于CT圖像診斷新冠肺炎準確率為90%，可在20秒內完成一例CT圖像的檢測。目前該系統已利用云平臺實現多點部署，在中國多個省市開展AI輔助診斷。在互聯網上登錄http://ncov-ai.big.ac.cn/即可注冊使用該試用輔助診斷系統，首頁用戶手冊中附有注冊聯系方式和技術支持聯系方式。

Distinguished foreign experts and friends:

With the concern and support from friends all over the world, the COVID-19 containing in China shows a positive trend. The Chinese people fight against the epidemic in a united and scientific way. A number of provinces and cities witness continuous zero-increase of newly con firmed cases. On the premise of ensuring epidemic prevention and control, the Chinese government helps enterprises and institutions to resume production and operation. Every effort is made to minimize the negative impact on economic development and boost confidence in prosperity and stability of the world's economy.

In this battle, our scientific and technological practitioners work hard at the forefront of related research projects. Some amazing achievements have exerted active effects in the epidemic prevention and control. The Chinese government from the start acts in an open, transparent and honest manner, and shares information and research progress with World Health Organization (WHO) and the international community. We make all efforts to prevent the epidemic from spreading. Here, I would like to introduce some successful practices in Guangdong province, where I live and work.They are proved to be effective in epidemic control and medical treatment.We are happy to share with you all for exchange and cooperation and provide related services if needed.

First, trial of AI-aided COVID-19 Diagnostic System. Imageological examination plays an important role in the diagnosis of novel coronavirus pneumonia. The epidemic is a newly emerging disease featured with rapid deterioration. CT scans are repeatedly used to confirm cases, monitor disease progression and evaluate therapeutic effect. However, it is hard for doctors to make quick comparison and lesion change recognition only through visual examination. Based on about 500,000 clinical images, Guangzhou Regenerative Medicine and Health Guangdong Laboratory and Sun Yat-Sen Memorial Hospital af filiated with Sun Yat-Sen University work together to develop the AI-aided COVID-19 Diagnostic System. Featured with chest-CT and X-ray imageology, the System can differentiate COVID-19 patients from non-COVID-19 patients ef ficiently and speci fically (including patients of other viral pneumonia, bacterial pneumonia or other patients with fever). It can complete the detection of one CT scan in 20 seconds with the diagnostic accuracy of 90%. In China, it has been deployed in many provinces and cities to aid the diagnosis through cloud platform. If needed, please check the website http://ncov-ai.big.ac.cn/ and register for the trial of the AI-aided diagnostic system. Contact for registration and technical support can be found in the User's Manual on the homepage.

二是云腦支持科研抗疫。廣東鵬城實驗室擁有國內首個人工智能基礎開源開放平臺——鵬城云腦，現有AI算力100P FLOPS@FP16（每秒十億億次半精度浮點計算）。在疫情期間，任何針對本次新型冠狀病毒的基因測序、蛋白篩選、疫苗和藥物研發的公共科研機構、學校、醫院都可以通過郵件anti-2019-nCoV@pcl.ac.cn聯系鵬城實驗室，并提交研究的主要方向和預期成果，鵬城實驗室有專人在第一時間回復，由專業評估小組進行方案評估，并為評估通過的研究方案免費提供相應的AI算力支持。歡迎世界各國廣大科研人員提出最新的研究方案，共同為抗擊新型冠狀病毒貢獻力量。目前，鵬城實驗室云腦平臺提供的算力支持，已推動中國在病毒傳播預測、藥物篩選與疫苗研發、臨床早期診斷等方面取得多項進展，相關病毒傳播預測模型已開始試點應用，算力支持的藥物篩選發現一些老藥對新冠病毒具有良好體外活毒對抗效果，加速了臨床試驗的開展。

2020年3月19日，時任廣東省科技廳廳長王瑞軍（右二）在廣東科學中心調研隔離椅和隔離診臺

Second, Cloud Brain supporting anti-epidemic research. Peng Cheng Cloud Brain under Peng Cheng Laboratory is the first open source platform in China based on arti ficial intelligence with the AI computing power of 100 PFLOPS @ FP16. During the epidemic, the public research institutions, universities and hospitals involved in coronavirus-related gene sequencing, protein screening, vaccine and drug R&D are welcome to contact Peng Cheng Laboratory (anti-2019-nCoV@pcl.ac.cn) and submit scheme description of research direction and expected outcomes. Peng Cheng Laboratory will give a reply as soon as possible. The professional evaluation panel will provide a scheme evaluation accordingly and the approved proposals will be supported by free AI computing power.We welcome researchers worldwide to work together to fight against coronavirus. The computing power support of Peng Cheng Cloud Brain Platform has so far promoted the development progresses in terms of virus transmission prediction, drug screening, vaccine R&D, early clinical diagnosis, etc. Moreover, pilot application of related virus transmission prediction models has been carried out. With the assistance of the computing power, drug screening results show that some existed drugs have positive in vitro anti-viral effect upon COVID-19 virus. It accelerates the process of clinical trials.

Third, the detecting products for COVID-19. Real-Time Fluorescent RTPCR Kit for Detecting the 2019 Novel Coronavirus developed by BGI Group Co., Ltd. has been applied in more than 20 countries worldwide.BGI is capable of producing 200,000 PCR test reagents, 10,000 sequencing test reagents and 500,000 antibody test reagents on a daily basis. With 14 Huo-Yan Laboratories to do the emergency detecting, the nucleic acid/ antibody test of BGI is up to 50,000 reagents per day (Email: info@bgi.com, Contact: Yunping Zheng, Mobile: +86 13600002151). The COVID-19 Nucleic Acid Detection Kit (PCR-fluorescence method), developed by DAAN Gene Co., Ltd. of Sun Yat-Sen University, is among the first batch of COVID-19 detection products registered and approved in China. The accumulated output is almost 5 million reagents, which have been used extensively to detect the novel coronavirus (Email: alice@daangene.net,Contact: Yongmei Jin, Mobile: +86 18620055688). The COVID-19 Antibody Detection Kit (Lateral Flow Method), developed by Guangzhou Wondfo Biotech Co., Ltd., is the first antibody detection reagent approved in China which is capable of detecting novel coronavirus antibody in human serum, plasma, and whole blood. There are also 3 Wanfo antibody detection kits granted the CE certi fication in Europe, i.e. Wondfo SARSCoV-2 Antibody Test (Lateral Flow Method), Finecare SARS-CoV-2 IgM Test, Finecare SARS-CoV-2 Antibody Test (Email: pm@wondfo.com.cn,Contact: Fei Chen, Mobile: +86 13632361458).

三是新冠病毒檢測技術產品。深圳華大生物科技有限公司研制的新型冠狀病毒核酸檢測試劑盒（熒光PCR法），已經在全球20多個國家得到應用，該公司擁有日產20萬人份PCR檢測試劑、1萬人份測序檢測試劑、50萬人份抗體檢測試劑的能力，擁有14個“火眼”實驗室，每天能夠完成5萬人份核酸或抗體檢測能力（郵箱：info@bgi.com，聯系人：鄭云平，電話：13600002151）。中山大學達安基因股份有限公司研制的新型冠狀病毒核酸檢測試劑盒（熒光PCR法），為中國國內首批獲得注冊審批的新冠病毒檢測技術產品，目前累計生產了近500萬人份，廣泛用于新型冠狀病毒的檢測（郵箱：alice@daangene.net，聯系人：金詠梅，電話：18620055688）。廣州萬孚生物技術股份有限公司研制的新型冠狀病毒抗體檢測試劑盒（膠體金法），為中國國內獲批的首個抗體檢測試劑，能夠檢測人血清、血漿、全血中的新型冠狀病毒抗體；該公司還有3個新型冠狀病毒抗體檢測試劑獲歐盟CE準入資格，分別為Wondfo SARS-CoV-2 Antibody Test（Lateral Flow Method）、Finecare SARS-CoV-2 IgM Test、Finecare SARS-CoV-2 Antibody Test（郵箱：pm@wondfo.com.cn，聯系人：陳飛，電話：13632361458）。

四是院感防控新設備。廣州安捷生物安全科技股份公司（鐘南山院士產學研團隊成員）針對新冠肺炎疫情的防控，提出“單人隔離、即時消殺”的創新研發理念，自主創新研制了一系列隔離防控器械產品：負壓隔離病床、醫用隔離診臺、隔離凈化椅、開放式隔離病床、兒童隔離病床等。在本次疫情期間，該批產品在廣東省人民醫院、中山一院、廣醫一院、301海南醫院等各大醫療機構的發熱門診、呼吸科/傳染科病房、候診大廳、輸液廳、隔離區、機場、出入境海關等呼吸感染相關場所應用，隔離防控的效果明顯、獲得用戶高度的認可和好評。產品特點是持續即時收集和處理單個病人呼吸的可能帶病原氣體，即時消除、防控病人與其他易感人群之間的傳染，可阻斷呼吸傳染病傳播，減少感染發生。該公司歡迎世界各國的醫療機構聯系對接，可合作共建當地的呼吸傳染隔離防線，也歡迎一些設備生產企業對接聯合加盟生產（CLG86@163.com）。

Fourth, new equipment for hospital infection prevention. Focusing on the prevention and control of COVID-19, Guangzhou Angel Biosafety Science and Technology Co., Ltd. (member of the industry-universityresearch team of Dr. Nanshan Zhong) puts forward the innovative R&D concept of “solo quarantine, immediate sterilization”. With this concept, a series of products used for quarantine, prevention and control are developed, including the hospital beds for negative pressure quarantine/open quarantine/children quarantine, the medical isolation diagnosis table, the isolation purification chair, etc. These products have been applied at places with higher risk of respiratory infections,including airports, customs and fever clinics, pneumology/infectious departments, waiting halls, infusion halls, isolation areas of the medical institutions, e.g. Guangdong Provincial People’s Hospital, the First Af filiated Hospital, Sun Yat-Sen University, the First Af filiated Hospital of Guangzhou Medical University, Hainan Hospital of PLA General Hospital. The application performance of these equipment are signi ficant in the epidemic prevention and control, and are highly recognized and praised by the users. The feature of the products is to collect and process the expired gas instantly and constantly from the individual of con firmed cases which could carry pathogen. It can ef ficiently eliminate and control the possibility of person-to-person transmission between patients and susceptible population. In this way, it helps to block the spread of respiratory infectious diseases and reduce the incidence of infection. Medical institutions around the world are welcome to contact the company (CLG86@163.com) to co-build the defense line to prevent local respiratory infection. Manufacturers are also welcome to join the equipment production.

Fifth, the washable protective masks for civil use. Advanced Energy Science and Technology Guangdong Laboratory develops a kind of washable protective masks for civil use based on the heavy ion technology. Such mask is made of the washable heavy ion microporous membrane material instead of the melt-blown fabric which is in short supply during the epidemic. The air could go through the tiny holes on the microporous membrane material and the aerosol and bacteria will be blocked with no need to spray any other chemical reagents. Tested by the authority institute, PFE of such mask can reach 76.6%, considerably higher than the 30% standard of medical surgical mask. The Laboratory is open to the researchers, enterprises and organizations worldwide to improve the performance of the product. Purchase orders from other countries are welcome. For details, please contact the Laboratory(modan@impcas.ac.cn).

五是可清洗民用防護口罩。先進能源科學與技術廣東省實驗室利用重離子技術開發了可清洗民用防護口罩。該口罩不采用市面緊缺的熔噴布，而是采用可水洗的重離子微孔膜材料，通過膜上細微的小孔達到通過空氣、阻攔氣溶膠和細菌的目的，無須噴涂任何化學試劑。經權威機構檢測，該口罩的顆粒過濾效率可達76.6%，遠高于醫用外科口罩顆粒過濾效率30%的標準。該實驗室歡迎世界各國廣大科研人員和企業、團體對接共同研發不斷提升產品性能，同時也支持國外供貨商采購產品，疫情期間可以通過郵件modan@impcas.ac.cn聯系實驗室。

六是臨床試用藥物。磷酸氯喹（簡稱氯喹）具有廣泛抗病毒及抗冠狀病毒的作用，臨床研究結果顯示氯喹或可提高新冠肺炎患者的救治成功率、縮短住院時間及改善預后。在廣東省磷酸氯喹治療新冠肺炎的臨床試用研究中，累計入組磷酸氯喹治療新冠肺炎患者120例，其中輕型9例，普通型107例，重型4例，平均用藥后4.4天轉陰，無1例發展為危重型，目前已出院81例。用藥過程中，暫未發現嚴重不良反應。磷酸氯喹被納入國家衛健委、中醫藥局發布的《新型冠狀病毒肺炎診療方案（試行第六版）》（http://www.nhc.gov.cn/yzygj/s7 653p/202002/8334a8326dd94d329df351d7da8a efc2.shtml.）以及2月29日廣東省藥事管理質量控制中心發布的《新型冠狀病毒肺炎臨床合理用藥廣東專家共識（第二版）》（https://mp.weixin.qq.com/s/MiRwtFYbJy3u-0P0V-CbWw）。可以通過郵件shanpingjiang@126.com聯系江山平教授科學指導磷酸氯喹的用藥使用。

當前，中國疫情暴發態勢得到有效遏制，全球新冠疫情卻呈現快速增長態勢，多國確診病例不斷上升，國際疫情防控形勢嚴峻。我們對于疫情在世界其他國家的蔓延感同身受，真誠愿與各國分享科研成果、交流經驗，深化國際科技合作，竭盡全力幫助其他國家抗擊疫情。

“孤舉者難起，眾行者易趨。”這次疫情再次給國際社會帶來深刻啟示：我們的命運緊密相連，休戚相關。讓我們守望相助，攜手抗疫，早日打贏這場阻擊戰。

祝您幸福安康！

聯合國科技促進發展委員會（UNCSTD）第22屆副主席廣東省韶關市人民政府市長，原廣東省科學技術廳廳長王瑞軍 博士

(廣東省科技廳供稿）

Sixth, drugs for clinical trials. Chloroquine phosphate (chloroquine) has a wide range of antiviral effects, including anti-coronavirus. Results of clinical research show that treating the patients diagnosed as novel coronavirus pneumonia with chloroquine might improve the success rate of treatment, shorten hospital stay and improve patient outcome.According to the statistics, 120 patients were enrolled in the chloroquine treatment group in the clinical trial research in Guangdong, of which 9 mild cases, 107 ordinary cases, 4 severe cases; the patients were tested negative after drug treatment for 4.4 days on average with none of them developed into critical case, and 81 cases were discharged from hospital.So far, there is no serious adverse reaction observed in the medication.The drug (chloroquine) is included in the Guidelines for the Prevention,Diagnosis, and Treatment of Pneumonia Caused by COVID-19 (Trial Edition 6) issued by the National Health Commission and the National Administration of Traditional Chinese Medicine of the People's Republic of China (http://www.nhc.gov.cn/yzygj/s7653p/202002/8334a8326dd 94d329df351d7da8aefc2.shtml) and the Experts Consensus on Rational Clinical Drug Use in Guangdong for Treatment of Pneumonia Caused by COVID-19 issued by Guangdong Pharmacy Administration & Quality Control Center on 29th, February, 2020. Any inquiry of chloroquine,please contact Prof. Shanping Jiang (shanpingjiang@126.com).

At present, the epidemic in China is effectively contained. However, it shows a rapid increase around the world. The number of con firmed cases is climbing in many countries and regions. The epidemic becomes more and more severe. Truly empathizing with the people facing the epidemic in other countries, we stand ready to share our experiences and scienti fic achievements, deepen the international S&T cooperation, and offer as much assistance as we can. Let's form a strong concerted force to beat the disease.

There is a Chinese saying,“The going is difficult when doing it alone;the going becomes easier when doing it with many others.” The novel coronavirus epidemic gives the international community a profound inspiration that humanity should be seen as one community with a shared future. Let's look out for one another, and join hands to tackle the risks and challenges. The victory over the pandemic will surely come out in the near future.

Wish you happiness and good health!

Dr. Ruijun Wang

Vice-Chairman of the 22nd Session, UNCSTD Mayor of Shaoguan City, Guangdong Province, P.R.C Former Director General of Department of Science and Technology of Guangdong Province, P.R.C